The Evolution of Chimeric Antigen Receptor T-Cell, Bispecific Antibodies and Antibody-Drug Conjugates for the Treatment of Multiple Myeloma - PubMed
6 hours ago
- #Multiple Myeloma
- #Immunotherapy
- #CAR T-Cell
- Modern immunotherapies, including CAR T-cell therapies, bispecific antibodies, and antibody-drug conjugates, are reshaping multiple myeloma treatment, offering deeper responses and prolonged survival.
- These therapies are approved in relapsed/refractory settings and are being integrated earlier, including at diagnosis, with novel constructs like trispecific antibodies and dual-target CAR T-cells under investigation.
- Despite efficacy, they pose distinct toxicities such as cytokine release syndrome, neurotoxicity, increased infection risk, and ocular toxicity, requiring careful management.
- The review discusses efficacy, safety profiles, and sequencing strategies based on clinical trials and real-world studies.